Markets
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(3)
About
Aurobindo Pharma Ltd.
NSE: AUROPHARMA
|
BSE: 524804
|
ISIN: INE406A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Turnaround Potential
1220.7000
9.20
(
0.76
%)
NSE
Feb 26, 2026
15:31 PM
Near 52W High of ₹1278.60
Volume:
2.4M
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Aurobindo Pharma Ltd.
10 Feb 2023
US FDA Approval
1220.70
0.76%
Aurobindo Pharm
Hold:
Aurobindo Pharma Ltd.
by
Sharekhan
Target: 516
Recommendation
Target
Sharekhan
ICICI Direct increased Buy price target of Aurobindo Pharma Ltd. to 1425.0 on 15 Feb, 2026.
More from Aurobindo Pharma Ltd.
Recommended
Profit expectations across industries grow more sensitive to costs
The Baseline |
26 Feb 2026, 06:30PM
We tracked 5 years of IPOs. Some hard truths for investors about returns
The Baseline |
26 Feb 2026, 04:43PM
A deal is called off, increasing the chance for Aurobindo Pharma to be debt free
|
15 Jul 2020